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Background: Numerous preclinical and clinical studies have investigated the regenerative potential and the trophic
support of mesenchymal stem cells (MSCs) following their injection into a target organ. Clinicians favor the use of
smallest bore needles possible for delivering MSCs into vascular organs like heart, liver and spleen. There has been
a concern that small needle bore sizes may be detrimental to the health of these cells and reduce the survival and
plasticity of MSCs.
Methods: In this report, we aimed to investigate the smallest possible bore size needle which would support the
safe delivery of MSCs into various tissues for different clinical or cosmetic applications. To accomplish this we
injected cells via needle sizes 24, 25 and 26 G attached to 1 ml syringe in the laboratory and collected the cells
aseptically. Control cells were ejected via 1 ml syringe without any needle. Thereafter, the needle ejected cells were
cultured and characterized for their morphology, attachment, viability, phenotypic expression, differentiation
potential, cryopreservation and in vivo migration abilities. In the second phase of the study, cells were injected via
26 G needle attached to 1 ml syringe for 10 times.
Results: Similar phenotypic and functional characteristics were observed between ejected and control group of
cells. MSCs maintained their cellular and functional properties after single and multiple injections.
Conclusions: This study proves that 26 G bore size needles can be safely used to inject MSCs for clinical/
therapeutics purposes.
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Regenerative medicine is a multidisciplinary, young and
emerging field in biotechnology and medicine, which is
expected to change patient treatment profoundly, gener-
ating and regenerating tissues and organs instead of
merely ameliorating symptoms. Stem cells is a branch of
regenerative medicine treating damaged tissues by intro-
ducing progenitor cells into a tissue or organ and is
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reproduction in any medium, provided the ordiseases such as Alzheimer’s, Parkinson’s, heart disease,
rheumatoid arthritis, osteoarthritis and many others [1].
Mesenchymal stem cells (MSCs) have become a popular
source for cell therapy research because they are multi-
potent with the capability to differentiate into a variety
of cell types including osteocytes, chondrocytes, adipo-
cytes and myocytes under specific culture conditions [2].
They were initially characterized by Friedenstein and co-
workers more than 40 years ago, and were described as
fibroblast-like cells with the property of adhering to
plastic in culture [3]. Bone marrow is the conventional
source of MSCs; later these cells have been isolated
from variety of tissues from head to toe [4-6]. The
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minimal criteria to define human MSCs. As per these
criteria MSCs must be plastic-adherent, they must ex-
press CD105, CD73 and CD90; lack expression of CD45,
CD34, CD14 or CD11b, CD79alpha or CD19 and HLA-
DR surface molecules and they must differentiate to
osteoblasts, adipocytes and chondroblasts in-vitro in re-
sponse to specific stimuli [7]. MSCs also express wide
variety of cell surface and adhesion molecules such as
STRO-1, ICAM-1/2, ALCAM-1, L- selectin [8]. MSCs
repair the damaged tissues by secreting trophic factors
such as chemokines, cytokines, and extracellular matrix
proteins [9] apart from their regeneration ability.
The role of stem cells in the clinical field has gathered
tremendous momentum over the last decade and MSCs
become a focus of interest for use in clinical therapies
for various diseases and injuries. Although adult stem
cells have been described from a wide range of adult tis-
sues, the well characterized source for adult stem cells is
still bone marrow. BM-MSCs are an excellent candidate
for cell therapy because (a) they can be easily isolated
and expanded to clinical scale in a very short period of
time; (b) ease of accessibility; (c) can be biopreserved
with minimal loss of stem cell characteristics; (d) im-
munosuppressive nature and, (e) most importantly, so
far human clinical trials of MSCs have shown no ad-
verse reactions in either allogeneic or autologous
transplantation scenario [2]. In fact, clinical trials have
revealed the feasibility and safety of the clinical use of
MSCs and have provided some evidence of efficacy in
various medical conditions [10]. Immunomodulatory
functions of MSCs make them as an important candi-
date for the treatment of autoimmune diseases [11]
such as rheumatoid arthritis [12], Type 1 diabetes [13]
and multiple sclerosis [14,15]. Furthermore, adult stem
cells have helped to prevent corneal degeneration and
to restore vision in cases of blindness [16]. They have
also restored proper cardiac function to heart attack
sufferers [17] and improved movement in spinal cord
injury patients [18].
Recent guidelines issued by the regulatory body CBER
(Center for Biologics Evaluation & Research) suggests
that cell therapy products should have 80% viability or
more and show a repeatedly high level of potency [19].
Numerous studies have analyzed various factors which
could affect the cell viability and other parameters dur-
ing and after cell delivery [1,20]. Many of the methods
of cell delivery require the use of syringes to deliver the
cells to the appropriate site, for instance, multiple injec-
tions are made to the left ventricular myocardium when
treating heart failure due to ischemic disease. While phy-
sicians always prefer to use narrow bore needles for the
comfort of the patient or to prevent unnecessary bleed-
ing; the narrowed bores may cause damage to the cellsduring the passage through the needle. The size of the
needle could have an effect on cell viability and func-
tional changes could be induced by the stress of expul-
sion of the suspension from a narrow bored-sized
needle. Thus, we designed this study to determine the
impact on BM-MSCs while injecting them via different
bore-size needles. Further, we also evaluated the effect of
repeated injections on BM-MSCs via 26 G bore size
needle.
Material and methods
MSC isolation and culture
MSCs were obtained from bone marrow samples of
healthy donors aged between 20–35 years after obtaining
informed consent and the protocol was approved by the
institutional ethics committee (Manipal Hospital, Banga-
lore). MSCs were isolated as reported by us earlier [21].
Briefly, bone marrow mononuclear cells (MNCs) were
separated by the Ficoll density gradient method
(1.077 g/ml density) in 50 ml centrifuge tubes (Falcon,
Becton-Dickinson). Bone marrow MNCs accumulated
on the Ficoll–plasma interface were isolated and washed
again with KO-DMEM. Isolated cells were plated into
T-75 cm2 culture flasks (Falcon, Becton-Dickinson) and
cultured in KO-DMEM supplemented with 10% fetal bo-
vine serum (FBS; HyClone), 2 mM glutamax and Pen-
Strep (Gibco–Invitrogen) and incubated at 37°C and 5%
humidified CO2. Cells were supplemented with fresh
media every 48 h and upon confluency, the cells were
harvested with 0.25% trypsin–EDTA (Gibco–Invitrogen)
and re-plated in suitable tissue culture dishes for
expansion.
Injection of MSCs via different bore size needles
MSCs were injected via different bore size needles such
as 24, 25 and 26 G (all needles from Becton & Dickinson)
attached to 1 ml syringe with the flow rate of 2000
microl/min. Control group of cells were passed through
the 1 ml syringe without needle and cultured at 37°C and
5% Co2 incubator (Binder). During the second phase of
the study, cells were continuously injected for 10 repeats
(multiple injections) via 26 G needle. The MSCs ejected
for 2nd, 4th, 6th, 8th & 10th time were characterized for
morphology, viability, phenotypic expression and differ-
entiation potential to study the effect of multiple injec-
tions on MSCs.
Cryopreservation and resuscitation
MSCs were re-suspended in freezing solution containing
90% (v/v) sterile FBS and 10% (v/v) dimethylsulfoxide
(DMSO; Sigma). Cells were loaded in 2 ml cryovials
(Nunc) at a concentration of 3 × 106 cells/vial and frozen
using a programmable slow freezing unit (Planar Kryo
560-16). After freezing, the cryovials were transferred in
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bourne Cryogenics; BioSystem 36) for long term storage.
The frozen stocks were thawed in a constant-
temperature water bath at 37°C by shaking lightly. After
1 or 2 min, cells were re-suspended in complete medium
and centrifuged at 1800 r.p.m. for 10 min. MSCs were
thawed and injected through 26 G needle and analyzed
for percentage of cell viability, stromal marker expres-
sion and remaining cells were cultured to study their dif-
ferentiation potential.
CM-DiI labeling of MSCs
For detection of MSCs in-vivo, we have labeled the cells
using CM-DiI fluorescent dye (invitrogen). Cells were
removed and centrifuged at 1200 rpm for 10 min and
the supernatant was discarded. 25 million cells were re-
suspended in KO-DMEM (Gibco) along with 4 μM of
CM-DiI dye and incubated for 30 min at 37°C. Cells
were washed twice with KO-DMEM to remove the un-
bound dye. The cell pellet was re-suspended in 500 μL
of DPBS (invetrogen) for subsequent in-vivo transplant-
ation and tracking studies.
In-vivo injection and tracking of DiI labeled MSCs
Eight-ten weeks old Nude rats were used in our studies
with prior ethical approvals and all animal procedures
were performed in accordance with our institutional
guidelines. Animals were anesthetized by using isoflur-
ane in the induction chamber of In Vivo Imaging System
(IVIS; Caliper Life Sciences) and the cells were delivered
intravenously (i.v) by tail vein injection. Then the ani-
mals were placed in the IVIS imaging chamber which
consists of a supersensitive cooled charge-coupled device
(CCD) camera mounted inside a light-tight imaging
chamber. The gray scale photographic and fluorescent
images were superimposed using the Living Image V 4.2
software overlay (Caliper Life Sciences).
Determination of viability
Cell viability was assessed by 7-amino actinomycin D
(7-AAD) staining using flow cytometry as described
earlier [5].
Immunophenotyping by flow cytometry analysis
MSCs were harvested and resuspended in PBS at a cell
density of 1.0 × 106 cells/ml. Two hundred microliters of
the cell suspension (approximately 1 × 105 cells) was
incubated with the labeled antibodies in dark for 30 min
at room temperature (RT). The following antibodies
were used to mark the cell surface epitopes-CD90-
phycoerythrin (PE), CD44-PE, CD73-PE, CD166-PE
and CD34-PE, CD45-fluoroisothyocyanate (FITC), and
HLA-DR-FITC (all from BD Pharmingen, San Diego,
CA). At least 10,000 events were acquired on GuavaTechnologies flow cytometer, and the results were ana-
lyzed using Cytosoft, Version 5.2, Guava Technologies,
Hayward, CA.
Determination of cell senescence by β-galactosidase
assay
Senescence assay was performed with the MSCs cul-
tured after injection via different bore size needles using
Senescence β-Galactosidase Staining kit (Cell Signaling
Technologies, Danvers, MA, USA,) according to the
manufacturer’s protocol. Senescent cells were identified
as blue-stained cells by standard light microscopy, and a
minimum of 100 cells were counted in 10 random fields
to determine the percentage of SA-ß-galactosidase-posi-
tive cells [22].
Differentiation potential of MSC
To assess the mesodermal differentiation potential,
MSCs were cultured at a density of 1000 cells/cm2 in six
well plates (Nunc) and were allowed to reach confluence.
Differentiation potential of MSCs towards osteogenic,
chondrogenic and adipogenic potential was assessed
using published protocols [5].
Statistical analysis
All the experiments were replicated three times (n = 3).
Data was presented as mean ± SEM, and results were
analyzed by student t-test. Differences were considered
statistically significant when P <0.05.
Results
Effect of different bore size needles on MSC
characteristics
We conducted the entire study in two phases to identify
the smallest bore size needle for the safe delivery of
MSCs. During the first phase of the study, cells were
injected through different bore size needles (24 G, 25 G
and 26 G) and characterized them in comparison with
control cells (Figure 1 A). We showed that single injec-
tion of cells via 26 G was safe and non detrimental to
the biology of the cell. In the next phase, we checked
the effect of multiple injections of MSCs via 26 G bore
size needle.
Effect of needle bore sizes on cell attachment,
morphology and viability of MSCs after injection
Cells were plated in 6 well tissue culture dishes after
injected through variety of bore size needles such as
24 G, 25 G and 26 G to examine their attachment pat-
tern and cell morphology. All the injected group of cells
attached within 24 hours of plating and showed normal
spindle shape MSCs morphology similar to that of con-
trol cells (Figure 1B-E). High percentage of viability was
retained for the ejected group of cells through different
Figure 1 Characterization of BM-MSCs injected via different bore size needles: (A) Describes phase I study design flow chart. (B - E)
Represent the morphology; (F - I) viability; and (J - M) senescence studies of BM-MSCs injected via different bore size needles ranging from 24 G
to 26 G respectively along with the control cells injected via syringe with our any needle.
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cells via different bore sizes such as 24 G, 25 G and
26 G was compared with the viability of control cells
which were injected via syringe without attached to any
bore size needles (Figure 1F-I). No significant differences
were observed between the injected groups when com-
pared with control group of cells. During the second
phase of the study, percentage of cell viability remains
virtually same for all multiple injections (Table 1).MSC senescence after injecting through different bore
size needles
The enzyme lysosomal pH6 β-galactosidase (SA-β-gal)
was employed as a senescence marker to look at the per-
centage of cells undergoing senescence after injection.
Very few cells were found to express SA- β-gal stain,Table 1 Viability and phenotype of BM-MSCs ejected via 26 G
Control 2nd Jab 4th Jab
Viability 98.25% ± 1.45 96.98% ± 2.11 97.38% ± 2
CD44 98.68% ± 1.42 98.89% ± 1.18 98.13% ± 1
CD73 98.97% ± 1.16 98.63% ± 1.36 98.48% ± 1
CD166 96.48% ± 2.24 97.12% ± 2.16 96.29% ± 2
CD34 0.02% 0.23% 0.76%
CD45 0.06% 0.66% 0.47%
HLA-DR 0.05% 0.11% 0.76%suggesting that these cells were not damaged during the
injection process. Moreover, we observed a very small
percentage of SA-β-gal positivity for all injected group
of cells when compared with controls (Figure 1J-M).
These results indicate that there were no significant dif-
ferences observed for both manipulated and control
group of cultures.Surface phenotype characterization
Flow cytometry analysis revealed stromal marker expres-
sion of injected and control group of cells. Cells injected
via different bore size needles showed the positive expres-
sion of the MSC markers CD44, CD73 and CD166 and
negative for CD34, CD45 and HLA-DR similar to that of
the un-manipulated cells (Figure 2). Phase two study dis-
closed insignificant differences among the stromal markerbore size needle for multiple times
6th Jab 8th Jab 10th Jab
.23 95.89% ± 1.89 96.18% ± 2.19 97.35% ± 1.95
.56 98.54% ± 1.39 98.72% ± 1.28 98.31% ± 1.49
.41 98.77% ± 1.29 98.22% ± 1.67 98.41% ± 1.37




Figure 2 Detection of surface marker expression of BM-MSCs: Phenotypic expression of BM-MSCs after ejected via different bore size
needles along with control cells were analyzed by flow cytometry. An open area represents an antibody isotype control for background
fluorescence and a shaded area shows signal from MSC surface marker antibodies. Representative histograms are depicted.
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tiple times retained their high percentage of stromal mar-
ker expression (Table 1). As expected, the expression of
CD34, CD45 and HLA-DR was found to be negative in all
cell groups confirmed their mesenchymal nature.
Differentiation potential of MSCs after injection
Multi-lineage differentiation into chondro-, adipo- and
osteogenic potential was analyzed for cells ejected forsingle injection via 24 G, 25 G and 26 G bore size nee-
dles and multiple injections via 26 G bore size needle.
Alcian blue staining was used to assess the formation of
proteoglycans, which confirmed chondrogenic differenti-
ation ability for single and multiple injections
(Figures 3A-D, 4G-L). Cytoplasmic inclusions of neutral
lipid vacuoles after adipogenic differentiation were
stained with Oil Red O for both single and multiple
injected BM-MSCs (Figures 3I-L, 4S-X). Similarly,
Figure 3 Differentiation studies: Multilineage differentiation potential of cultured BM-MSCs injected via different bore size needles
along with controls. (A - D) Chondrogenic differentiation potential was demonstrated by Alcian blue staining. (E - H) Formation of mineralized
matrix was detected by alizarin Red staining confirms the osteogenic differentiation. (I - L) Adipogenesis was confirmed by neutral oil droplet
formation stained with Oil Red O. (M) Represents viability, stromal marker expression and mesodermal tri-lineage differentiation potential of MSCs
ejected through 26 G needle after cryopreservation.
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ation in cultures were visualized by Alizarin red staining
for both groups (Figure 3E-H, 4M-R). Hence, we con-
clude that even after single or multiple injections, BM-
MSCs retained their potential to differentiate in vitro
towards osteo-, chondro-and adipogenic lineages.
MSCs ejected through 26 G needle after cryopreservation
and resuscitation retains their phenotypic expression
and differentiation potential
MSCs after thawing injected via 26 G needle and were
analyzed for their viability, stromal marker expression
and their tri-lineage mesodermal differentiation poten-
tial. Although there was slight reduction in cell viability,
the expression of cell surface markers and differentiation
potential into chondrogenesis, osteogenesis and adipogen-
esis of these cryopreserved MSCs (Figure 3M; 4) were
comparable with that of the control MSCs. These results
clearly favor the applicability of this technology forcryopreserved MSCs and their subsequent clinical/thera-
peutic use.
In-vivo migration of CM-DiI labeled MSCs
The CM-DiI labeled MSCs were injected into the tail
vein of the Nude rats using 26 G needle. In the control
animal without any cell injection, we did not observe
any signal except at the tail region (Figure 5A). This auto
fluorescence is because of the scales surrounding the tail
region of the Nude rats and this signal was persistent
throughout the study. However, 30 minutes after inject-
ing 25 million labeled cells into the tail vein of the Nude
rate, we saw a distinguishable signal at the upper thoracic
region over and above the control animal (Figure 5B).
Subsequently after 24 hours we observed detectable
greater migration of cells towards the abdomen and to
the lower limb regions (Figure 5C). These data sets
clearly suggest even in the in-vivo condition, MSCs
injected through 26 G needle maintain their integrity
Figure 4 Morphology and differentiation potential of BM-MSCs injected for multiple times via 26 G: (A) Represents phase II flow chart
study design. (B - F) Indicates the morphology of BM-MSCs after multiple injections. (G - L) Represents chondrogenesis; (M - R) osteogenesis;
(S - X) Adipogenesis of BM-MSCs injected for multiple times via 26 G bore size needle.
Figure 5 In-vivo migration of BM-MSCs injected into the tail vein using 26 G needle: (A) Represents control animal without cell
injection; (B) Indicates migration pattern of BM-MSCs after 30 minutes; (C) Represents grater migration ability of BM-MSCs after
24 hours of implantation.
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animal.Discussion
BM-MSCs have generated great excitement in the field
of regenerative medicine and are being investigated to
treat a wide variety of medical conditions. The route of
delivery is of essential importance for the outcome of
clinical trials using BM-MSCs. While physicians prefer
to use the narrowest bore needles for injection in order
to reduce patient discomfort and pain as well as to re-
duce oozing from the injection site, biologists have con-
cerns about the effect of the injection procedure on the
viability and biological activity of the cells. The main
concerns of cell delivery through very fine needles is that
the cells may not survive the shear force, and the larger
is the cell size, the more difficult it is for the cells to sur-
vive after ejection from the needle. MSCs on average are
usually between 8 – 20 microns in size which is signifi-
cantly larger compared to hematopoietic stem cells or
lymphocytes [23]. This raises the concerns among the
clinician community that MSCs could be damaged if
they are injected via small guage needles for direct sub-
cutaneous or intramuscular delivery into the skin,
muscle tissues and vascular organs like heart, liver and
spleen or i.v delivery. Our study clearly demonstrates
that MSCs could be successfully delivered into these tis-
sues using small guage needles without hampering the
biological activity of these cells. Some conditions, in-
cluding ischemic heart disease and critical limb ische-
mia, local injection or even multiple injections is
required, therefore, the safety of the cells plus needle as
a “combined product” causes much concern among reg-
ulators and clinical investigators. In this manuscript, we
have reported the viability, senescence, surface marker,
tri-lineage in vitro differential potential, cryopreservation
and in vivo tracking of BM-MSCs which were injected
through small gauge needles and those undergoing mul-
tiple injections, providing evidence that BM-MSCs are
robust and remain fit after needle injection.
Although the clinical applications of cell therapy are
still in their infancy, there is an urgent need to deter-
mine safe delivery systems where these cells retain their
viability and biological functionality [24]. There have
been a few recent studies investigating the actual effect
of cell suspension passing through a needle based deliv-
ery device; for example, Kondziolka and coworkers
assessed the viability of neuronal cells passed through a
25 -gauge needle and cannula using a simple trypan blue
exclusion method [25]. Heng and co-workers previously
reported the effects of injection through 26-Gauge Nit-
inol needle at different flow rate on MSCs [26]. In the
current study we have clearly demonstrated that theBM-MSCs retain their viability and biological function
after injecting through different bore size needles.
We also examined the status of 26 G needle injected
MSCs after cryopreservation. Though there was a slight
drop of cell viability, our data clearly demonstrated that
the 26 G needle ejected MSCs were able to maintain
their stromal phenotypes and differentiation potential
after cryopreservation and subsequent thawing
(Figure 3M). Our earlier reports and studies by other
research groups have showed that there would be 10 -
20% reduction in post thaw of cell viability [27,28]. In
consistence with these reports, here we have witnessed
similar drop of cell viability after cryopreservation and
thawing of 26 G needle ejected MSCs.
In certain indications of cell therapy such as the mul-
tiple intramuscular injections for critical limb ischemia,
repeated intra-muscular injections are made from the
same syringe. This study also attempted to mimic this
clinical condition as well. We also aimed to find out the
clinically relevant smallest possible bore size needles
which can be used for safe delivery of cells either by sin-
gle or multiple injections. We assessed the viability of
hMSCs following their ejection through three different
clinically relevant bore size needle gauges; 24, 25 and
26 G. The selection of an appropriate and safe needle
gauge used during a cell therapy application very much
depends on post delivery cellular and functional charac-
teristics, namely the viable cell density, phenotypic ex-
pression of the mesenchymal stromal markers, cell
senescence and the functional properties such as differ-
entiation of MSCs into mesoderm lineage. As such, cells
injected through various needle gauge sizes ranging from
24 to 26 G, have successfully demonstrated their cellular
and functional properties. During the second phase of
the study, cells were injected through 26 G bore size
needle multiple times to mimic certain clinical usage as
described above. Cells injected multiple times via 26
gauge bore size needle have also been shown to retain
their cellular and functional characteristics.
Since the clinical success of stem cell therapy, in other
words restoration of function, tissue integration and/or
cell localization [29] is based upon the post transplant-
ation response, the quality of cells injected are an im-
portant determinant of the clinical response. Thus, we
were interested to see the in-vivo migration of MSCs
after injecting trough the smallest bore size needle. Earl-
ier researchers demonstrated in-vivo migration ability of
MSCs [30,31]; however it was not clear about the needle
size used to deliver the cells. Here we have showed that
the MSCs injected via 26 G needle were safe and
migrated to various organs (Figure 5B-C). It has been
shown by other research groups that the MSC will mi-
grate to the thoracic cavity immediately after implant-
ation [32,33]. In consistency with these studies we also
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mediately migrated to the thoracic cavity after 30 min-
utes of injection (Figure 5B) and subsequently to the
abdominal cavity and towards the lower limbs after
24 hours (Figure 5C) of implantation. These results con-
firm that cells were healthy and able to migrate all over
the body in the normal healthy animal safely after inject-
ing through 26 G needle. Earlier most of the researches
applied the IVIV system to identify in-vivo migratory
properties of tumor cells in cancer biology. However,
here we have successfully demonstrated the usage of
IVIS system for studying in-vivo MSC migration pattern.
Conclusion and future perception
Although still in its infancy, cell therapy holds huge
promise for the treatment of many diseases with unmet
medical needs. It has already been demonstrated by
many researchers and clinical trials that the delivery of
cells is possible using conventional delivery systems,
which is via direct injection in situ. We have clearly
demonstrated that there is no significant difference in
viability and cellular responses caused by the delivery
system after post-ejection via different bore size needles
up to a minimum of 26 G. This study also further high-
lights that multiple injections of cells immediately to the
desired site is also safe and non detrimental for the cells.
Most clinicians would be comfortable with the use of
26 G needles for most clinical purposes. This makes it
possible to use direct needle injection into even vascular
organs, thus in future therapies, possible injections to
the heart muscle, liver, pancreas or even the spleen
would also be safe and non injurious to the cells.
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